The FDA has acknowledged receipt of a resubmission of the new drug application (NDA) for dapagliflozin, an SGLT-2 inhibitor for the treatment of type 2 diabetes…. Astra Zeneca and Bristol-Myers Squibb (BMS) have announced that the agency has issued a new Prescription Drug User Fee Act goal date of January …

‘Reprogrammed’ glucose uptake in the small intestine may explain why gastric bypass surgery can sometimes result in the early resolution of type 2 diabetes…. 

Skipping breakfast or eating late at night should top the not-to-do lists of men in middle age and beyond; not only do they have metabolic effects, they may also put men at higher risk for coronary heart disease…. 

Researchers just reported that skipping breakfast was linked to heart disease (see this week’s Item #5) but a few days later comes word that skipping breakfast could be a good weight-loss strategy because people don’t make up for all those calories later in the day…. 

According to the European Medicines Agency’s Committee for Medicinal Products for Human Use, current data linking glucagon-like-peptide-1 (GLP-1) agonists to adverse pancreatic events are not adequate….

A registry study affirmed that insulin glargine (Lantus) didn’t significantly raise cancer risk compared with "human" insulin…. 

In a new study, the diabetes drug rosiglitazone was not associated with an increased risk of major cardiovascular events and mortality in diabetic patients who had established CAD…. 

Danish hospital researchers show that the recommendation among conventional doctors and nutritionists to type 2 diabetes patients to lay off the fruit may be wrong…. 

Regular health assessments would reduce the incidence of diabetes and cardiovascular disease, and would also be cost-effective….

Resveratrol prevented gains in blood pressure, cholesterol and aerobic fitness….